Submit Manuscript  

Article Details


Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer

[ Vol. 19 , Issue. 1 ]

Author(s):

Qiuli Wang, Muwen Yang, Ye Zhang, Li Zhong and Xinyu Zheng*   Pages 54 - 65 ( 12 )

Abstract:


Background: Both Drosophila melanogaster deoxyribonucleoside kinase (Dm-dNK) suicide gene therapy and exogenous CD40 ligand (CD40L)-CD40 interaction in cancer via conditionally replicating adenovirus can selectively kill tumors without damaging normal tissues.

Objective: To further improve the cancer killing effect, we investigated the therapeutic effect of combined cancer gene therapy based on a selective oncolytic adenovirus vector containing Dm-dNK suicide gene and exogenous CD40L on breast carcinoma cells in vitro and in vivo.

Methods: A series of conditionally replicating adenoviruses using adenovirus vector P74 were generated: P74-dNK, P74-CD40L (expressing Dm-dNK or CD40L respectively), and P74-dNK-CD40L (expressing combined Dm-dNK and CD40L). Breast cancer cell lines (MDA-MB-231, MCF-7) and non-tumor cell line (MRC5) were treated with adenovirus and cytotoxicity determined by MTT assay, and apoptosis assessed by flow cytometry after 72h. We also assessed in vivo cell killing efficiency using a mouse xenograft model with MDA-MB-231 cells.

Results: Co-expression of Dm-dNK and CD40L reduced cell proliferation of MDA-MB-231 or MCF7 cancer cells, and induced more apoptosis in TERT and CD40 positive cancer cells, but not normal MRC5 cells. Significant reduction in tumor volume was also seen in combined treatment arms as compared to any single treatment.

Conclusion: Our data suggest enhanced, selective tumor cell killing using combined gene therapy with conditionally replicating adenovirus containing Dm-dNK suicide gene and exogenous CD40 ligation (CD40L-CD40).

Keywords:

Suicide genetic therapy, CD40 ligand, breast neoplasms, adenoviridae, oncolytic virotherapy, OVs.

Affiliation:

Department of Breast Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, Department of Breast Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, Lab 1, Cancer Institute, First Affiliated Hospital, China Medical University, Shenyang, Liaoning, Hebei University College of Life Sciences, Baoding, Hebei, Department of Breast Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning



Read Full-Text article